Established over 50 years ago, Marle has become one of the reference suppliers to the orthopaedic industry. The company provides specialized manufacturing services for the production of hip, knee, shoulder, spine and extremities implants as well as instruments of the highest quality.
Exclusively focused on orthopaedic manufacturing, Marle is a strategic and reliable long-term partner to Original Equipment Manufacturers all over the world, offering end-to-end manufacturing capabilities, from forging and casting through machining, polishing, coating and packaging services, allowing the company to offer “implants in the box” to its clients.
Headquartered in Lyon (France), Marle has 750 employees and runs six certified state-of-the-art production sites in France and Switzerland. The company generates annual revenues of circa €150m.
Florac invested in Marle in December 2019 alongside the family-investment holding company Dentressangle, the company's new majority shareholder since that date. IK Investment Partners, former majority shareholder since 2016, as well as the management team of the company, reinvested as part of the transaction.
With the takeovers of Finortho and SMB Médical, respectively in 2015 and 2017, Marle has strengthened its leadership in Europe and the company now aims to further develop internationally, particularly in the United States and in China, organically and through external growth operations.